Clinical Trial Detail

NCT ID NCT02892201
Title Pembrolizumab in HNSCC With Residual Disease After Radiation
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Yale University
Indications

hypopharynx cancer

oral squamous cell carcinoma

head and neck squamous cell carcinoma

oropharynx cancer

nasopharynx carcinoma

laryngeal squamous cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.